Boundless Bio gets FDA clearance for cancer drug trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
January 20, 2026 7:00 AM ESTBBI-940 IND accepted; initiation of first-in-human clinical trial on trackÂ
for the first half of 2026
Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second half of 2028
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative... More
